Poniard Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript

Poniard Pharmaceuticals, Inc. (PARD)

Q1 2010 Earnings Call

May 10, 2010 4:30 pm ET

Executives

Ronald Martell - CEO

Dr. Michael Perry - President & CMO

Greg Weaver - CFO

Susan Neath - Investor Relations

Analysts

Simos Simeonidis - Rodman & Renshaw

Presentation

Operator

» Poniard Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
» Poniard Pharmaceuticals Inc Q4 2007 Earnings Call Transcript
» Enzon Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript

Good day and welcome to the Poniard Pharmaceuticals first quarter 2010 earnings conference call. Today's conference is being recorded. At this time, I’d like to turn the conference over to Susan Neath. Please go ahead Susan.

Susan Neath

Good afternoon, and thank you for joining us to discuss the results of Poniard Pharmaceuticals first quarter 2010 earnings conference call. Poniard issued a press release this afternoon that is available on the company’s website at www.poniard.com.

Comments made on this call will contain forward-looking statements relating to the company’s picoplatin and product candidate and describing the company’s corporate strategies and objectives, regulatory and partnering efforts, product development activities, clinical and regulatory goals, financial conditions, future expectations, prospectus, projections and believes.

Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of important factors including risks and uncertainties inherent in the company’s business including the company’s anticipated future operating losses, future capital requirement and ability to obtain future funding.

Direct strategic partners relationships may not be established on a timely basis on terms that are ultimately favorable to the company or at all the potential safety efficacy and commercial viability of the company picoplatin product candidates, the risk that the company’s additional analysis of data some clinical trails of picoplatin may produce negative or inconclusive results are maybe inconsistent with previously announced results are previously conducted trials.